Organization | Zunyi Medical College

Zunyi Medical College Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4

Founded: Zunyi China (1947)

Organization Overview

First Clinical Trial

2016

NCT03266601

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

Affiliated Hospital of Zunyi Medical University | Second Affiliated Hospital of Zunyi Medical University | the Fifth Affiliated Hospital of Zunyi Medical University | Zunyi First People's Hospital | Zunyi Medical College | Zunyi Medical University Affiliated Hospital

Active Ingredients

Drugs in Phase 4 Trials (14)

acetylsalicylic acid (aspirin) (1 trial)

clopidogrel (plavix) (1 trial)

dapagliflozin (farxiga) (1 trial)

dexamethasone (1 trial)

etoposide (vepesid) (1 trial)

insulin aspart (Novolog) (1 trial)

interferon alpha-2b (Intron-A) (2 trials)

metformin (glucophage) (1 trial)

olanzapine (zyprexa) (1 trial)

ribavirin (virazole) (1 trial)

rivaroxaban (xarelto) (1 trial)

ruxolitinib (jakafi) (1 trial)

saxagliptin (onglyza) (1 trial)

ticagrelor (brilinta) (1 trial)

Drugs in Phase 3 Trials (2)

bat5906 (1 trial)

ranibizumab (lucentis) (1 trial)

Drugs in Phase 2 Trials (3)

ak104 (1 trial)

atorvastatin (lipitor) (1 trial)

bone marrow derived mesenchymal stem cells (1 trial)

Drugs in Other Trials (6)

beclomethasone (vanceril) (1 trial)

ceftazidime (fortaz) (1 trial)

dextrose (1 trial)

formoterol (foradil) (1 trial)

linaclotide (linzess) (1 trial)

polyethylene glycol (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Herpangina (Phase 4)

Infarction (Phase 2)

Lung Neoplasms (Phase 4)

Myocardial Infarction (Phase 2)

Nausea (Phase 4)

Vomiting (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 12
# of Trial APIs: 25